GWAG
ALNY icon

Garrett Wealth Advisory Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Garrett Wealth Advisory Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16
Closed -$1.29K – 80
2019
Q3 		$1.29K Buy
+16
New +$1.27K ﹤0.01% 667

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Garrett Wealth Advisory Group's ALNY Position: Q4 2019 in Review

Garrett Wealth Advisory Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2019, closing a stake of 16 shares — an estimated $1.29K sold.

Garrett Wealth Advisory Group first reported a position in ALNY in Q3 2019 and held it in 1 quarter. The position peaked at $1.29K in Q3 2019. 316 funds tracked by Wall St. Rank hold ALNY as of Q4 2019.

  • Garrett Wealth Advisory Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Garrett Wealth Advisory Group sold 16 Alnylam Pharmaceuticals shares in Q4 2019, an estimated $1.29K.
  • Garrett Wealth Advisory Group first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Garrett Wealth Advisory Group's Alnylam Pharmaceuticals position peaked at $1.29K in Q3 2019.
  • 316 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2019.

Based on Garrett Wealth Advisory Group's 13F filing for Q4 2019, filed 28 Jan 2020.